Boston Scientific brings on Abiomed exec as investor relations head; EU device reg revamp creates apprehension;

@FierceMedDev: Myriad partners up with BioMarin for cancer diagnostics. Yesterday's story | Follow @FierceMedDev

@MarkHFierce: OraSure dumped Roche in favor of Thermo Fisher for a drug testing Dx development deal. Strategic, not fickle. Yesterday's story | Follow @MarkHFierce

@MichaelGFierce: FDA allows pivotal trial of Actinium's armed-antibody isotope delivery. More from FierceDrugDelivery | Follow @MichaelGFierce

> Boston Scientific ($BSX) hired a veteran Abiomed ($ABMD) executive to be its new vice president of investor relations. Item

> Fisher & Paykel Healthcare, a New Zealand medical equipment manufacturer, reported record profit and higher revenues for the first half of its fiscal year. Item

> NeuroMetrix ($NURO) debuted a new website designed to help convey information to physicians and patients about chronic pain and the company's signature nerve stimulation device designed to address it. Item

> Finland's BonAlive Biomaterials gained a CE mark for the new ready-to-use moldable version of its osteostimulative bioactive glass bone regeneration putty. Item

> OrthoSensor will use Valtronic to manufacture its Verasense intelligent knee system. Item

> Observers are getting anxious about final efforts to revamp Europe's medical device regulations. Item

Biotech News

@FierceBiotech: Avalon jumpstarts first biotech in $500M GlaxoSmithKline portfolio deal. Article | Follow @FierceBiotech

@JohnCFierce: Lots of biotech startup news this month. Lots of deal flow in the pipeline. | Follow @JohnCFierce

@DamianFierce: Meet LEE011, Novartis's overnight celebrity breast cancer candidate. News | Follow @DamianFierce

@EmilyMFierce: Eli Lilly, Project A.L.S. forge preclinical drug discovery pact. Story | Follow @EmilyMFierce

> Regeneron, Sanofi hit a trio of goals in first PhIII test of rheumatoid arthritis drug. Story

> Novartis sneaks up on Pfizer with CDK4/6 cancer challenger. Article

> Food allergy startup bags $17M for oral immunotherapy. News

Pharma News

@FiercePharma: Thursday's best-read special report: Top 10 Patent Losses of 2014. Report | Follow @FiercePharma

@EricPFierce: Pfizer says it will close a Puerto Rico plant days after Merck says the same thing. Story | Follow @EricPFierce

@CarlyHFierce: Biogen Idec's MS pill Tecfidera wins 10 years' protection in EU. Analysts expect 36% of $4.5B in 2018 sales to come from non-U.S. More | Follow @CarlyHFierce

> Ariad's Iclusig further restricted by EMA. Story

> Novartis plans $5B share buyback, hints at restructuring. Article

> EU patent call sets stage for Tecfidera launch in Europe. Report

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.